Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints

Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety

A One Health trial design to accelerate Lassa fever vaccines

2 months / nature / David Simons

Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition

2 months / medcitynews / Frank Vinluan

Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug

2 months / endpoints / Elizabeth Cairns

Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months



Related Stories



Related Tags


Healthcare

HIMSS 2026 pushes real‑time data, cloud and interoperability playbook (16 hrs)

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

more #healthcare


Pharmaceuticals

Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma (17 hrs)

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival (20 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

more #pharmaceuticals


Public Health

Vitamin D trial shows reduced long‑COVID risk but no severity benefit (19 hrs)

FDA approves leucovorin for rare folate disorder despite autism hype (32 hrs)

AI improves UK breast-screening detection by about 10% (2 days)

more #publichealth


StackHealth Time Machine



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.